Lab
Fort Sanders Regional Medical Center
Fort Sanders Regional Medical Center was paid $26.76M by Medicaid between Jan 2018 and Dec 2024, across 141 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoFORT SANDERS REGIONAL MEDICAL CENTER
KNOXVILLE, TN 37916
KNOXVILLE, TN 37916
33aNPI1942294814assigned 09/07/2005
33bProvider typeClinical Medical Laboratory
28Total paid$26.76M
24GClaims761,145
24DCodes billed141
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#5 of 70
Median peer was paid$141K
This provider vs. median190×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,048 | $3.14M | |
| 2019 | 126,180 | $4.23M | |
| 2020 | 102,640 | $3.67M | |
| 2021 | 105,026 | $4.01M | |
| 2022 | 118,961 | $4.17M | |
| 2023 | 124,542 | $4.52M | |
| 2024incomplete | 73,748 | $3.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 34,395 | 31,588 | $9.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 16,079 | 14,605 | $6.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 24,742 | 23,040 | $3.91M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 17,740 | 16,048 | $575K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.1% | 18,089 | 16,452 | $567K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 82,030 | 74,392 | $412K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 4,402 | 4,146 | $378K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 3,470 | 1,674 | $312K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 11,364 | 9,328 | $293K |
| 80053 | Comprehensive metabolic panel | 1.0% | 56,830 | 49,982 | $272K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 12,048 | 11,070 | $270K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 14,242 | 13,401 | $268K |
129 more codes
| 86850 | <1% | 13,793 | $207K | |
| 84484 | <1% | 15,130 | $192K | |
| 71045 | Radiologic examination, chest; single view | <1% | 16,158 | $184K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,173 | $175K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,822 | $174K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,561 | $161K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 51,005 | $156K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 26,447 | $148K |
| 59025 | Fetal non-stress test | <1% | 1,914 | $147K |
| G0378 | Hospital observation service, per hour | <1% | 371 | $124K |
| 84702 | <1% | 8,168 | $121K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,141 | $112K |
| 86787 | <1% | 5,822 | $106K | |
| 86780 | <1% | 13,268 | $104K | |
| 86900 | <1% | 6,524 | $103K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,244 | $99K |
| 84144 | <1% | 5,355 | $83K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,347 | $78K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,941 | $77K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,823 | $74K |
| 83880 | <1% | 2,793 | $68K | |
| 43235 | <1% | 100 | $67K | |
| 82728 | <1% | 6,653 | $65K | |
| 86803 | <1% | 5,673 | $65K | |
| 83690 | <1% | 17,687 | $65K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,943 | $58K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,714 | $51K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,082 | $47K |
| 82951 | <1% | 4,292 | $43K | |
| 87276 | <1% | 8,550 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,716 | $40K |
| 86762 | <1% | 5,430 | $37K | |
| 86901 | <1% | 6,566 | $37K | |
| 87340 | <1% | 5,321 | $36K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 280 | $34K |
| 77336 | <1% | 863 | $34K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,485 | $32K |
| 81025 | <1% | 10,170 | $32K | |
| 87275 | <1% | 8,550 | $29K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 66 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 389 | $26K |
| 77334 | <1% | 152 | $24K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 550 | $24K |
| 83605 | <1% | 4,001 | $22K | |
| 11043 | <1% | 297 | $19K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 692 | $19K |
| 87081 | <1% | 4,253 | $18K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,114 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,442 | $17K |
| 81001 | <1% | 20,601 | $16K | |
| 84703 | <1% | 3,882 | $13K | |
| 83615 | <1% | 2,628 | $12K | |
| 84460 | <1% | 2,724 | $12K | |
| 87186 | <1% | 1,681 | $12K | |
| 84450 | <1% | 2,721 | $12K | |
| 87147 | <1% | 1,070 | $12K | |
| 84520 | <1% | 2,219 | $10K | |
| 84550 | <1% | 2,663 | $9K | |
| 82565 | <1% | 1,425 | $9K | |
| 85610 | <1% | 4,670 | $8K | |
| 85027 | <1% | 1,874 | $8K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 543 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 170 | $7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 126 | $6K |
| 81003 | <1% | 8,489 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,574 | $6K |
| 84134 | <1% | 1,315 | $6K | |
| 82077 | <1% | 2,164 | $6K | |
| 96417 | <1% | 120 | $5K | |
| 77300 | <1% | 48 | $5K | |
| 82947 | <1% | 960 | $5K | |
| 80061 | Lipid panel | <1% | 1,201 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 195 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 195 | $4K |
| 82570 | <1% | 776 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 84 | $4K |
| 84466 | <1% | 968 | $4K | |
| 82607 | <1% | 605 | $4K | |
| 84156 | <1% | 1,864 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 54 | $3K |
| 83540 | <1% | 1,228 | $3K | |
| 84439 | <1% | 446 | $3K | |
| 85730 | <1% | 602 | $3K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 21 | $3K |
| 74246 | <1% | 70 | $2K | |
| 84425 | <1% | 245 | $2K | |
| 82575 | <1% | 285 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 64 | $2K |
| 83735 | <1% | 701 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,470 | $2K |
| 82746 | <1% | 454 | $2K | |
| 77280 | <1% | 16 | $2K | |
| 87077 | <1% | 348 | $2K | |
| 82731 | <1% | 53 | $2K | |
| 77290 | <1% | 16 | $1K | |
| 87040 | <1% | 147 | $1K | |
| 85014 | <1% | 945 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 125 | $1K |
| 80076 | <1% | 437 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 246 | $1K |
| 96367 | <1% | 58 | $1K | |
| 84481 | <1% | 67 | $993.18 | |
| 82550 | <1% | 314 | $969.25 | |
| 83970 | <1% | 70 | $866.31 | |
| 96415 | <1% | 20 | $857.07 | |
| 74240 | <1% | 30 | $798.55 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $781.90 |
| 87522 | Neg quan hep c or qual rna | <1% | 29 | $579.75 |
| 87205 | <1% | 320 | $572.85 | |
| 87210 | <1% | 182 | $538.12 | |
| 87088 | <1% | 82 | $522.19 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 162 | $497.63 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 29 | $439.95 |
| 82553 | <1% | 242 | $396.45 | |
| 85379 | <1% | 56 | $383.78 | |
| 87070 | <1% | 294 | $375.53 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | $307.88 |
| 87075 | <1% | 120 | $131.84 | |
| 84145 | <1% | 14 | $81.21 | |
| 80177 | <1% | 16 | $61.74 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $58.95 |
| 73562 | <1% | 13 | $58.68 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 25 | $13.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,597 | $8.44 |
| 84100 | <1% | 12 | $3.25 | |
| A9270 | Non-covered item or service | <1% | 3,816 | $0.77 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,419 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 292 | $0.00 |
| 74022 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRINGER, RICK (VP REVENUE CYCLE)
Parent organizationCOVENANT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Parkwest Medical Center | Knoxville, TN | $29.88M |
| Leconte Medical Center | Sevierville, TN | $19.05M |
| Morristown Hamblen Hospital Association | Morristown, TN | $17.83M |
| Methodist Medical Center | Oak Ridge, TN | $11.32M |
| Roane County Medical Center | Harriman, TN | $9.24M |
| Cumberland Medical Center, INC. | Crossville, TN | $6.06M |
| Fort Loudoun Medical Center | Lenoir City, TN | $5.86M |
| Claiborne Medical Center | Tazewell, TN | $3.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.